AKAleksandra Kozioł

Aleksandra Kozioł

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aleksandra Kozioł has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Regional and systemic complications following glioma resection: a systematic review and meta-analysis

    by Katarzyna Słychan, Marcin Piersiak, Jakub Rubin, Aleksandra Kozioł, Michał Tyliszczak, Mateusz Pawłowski, Rafał Chojak

    Gliomas represent a heterogeneous group of primary brain tumors with variable biological behavior. High-grade variants, notably glioblastomas, exhibit aggressive growth and a poor prognosis. Although surgical resection is central to management, it may lead to systemic and regional postoperative complications that adversely affect outcomes. While neurological complications have been extensively studied, comprehensive analyses of non-neurological sequelae remain limited. This study aimed to estimate the pooled proportion of postoperative systemic and regional complications following glioma resection and to identify factors influencing these proportions. A systematic review and meta-analysis was conducted per PRISMA guidelines. PubMed, Web of Science, and Embase were searched for English-language articles published between January 2000 and November 2024 reporting postoperative complications in glioma resection patients. Pooled proportion were calculated using a random-effects model, and meta-regression assessed the impact of covariates including patient age, gender, publication date, geographical location, and sample size. Seventy-seven studies were included. The pooled proportions for postoperative complications were as follows: venous thromboembolism, 4.92% (95% CI: 1.51–10.05%); deep vein thrombosis, 4.75% (95% CI: 2.86–7.05%); urinary tract infection, 3.77% (95% CI: 0.81–8.47%); hydrocephalus, 2.53% (95% CI: 1.37–3.97%); pulmonary infection, 2.39% (95% CI: 1.15–3.99%); cerebrospinal fluid leak, 2.22% (95% CI: 0.99–3.87%); surgical site infection, 2.21% (95% CI: 1.48–3.07%); meningitis, 1.49% (95% CI: 0.47–2.96%); pulmonary embolism, 1.33% (95% CI: 0.74–2.06%); and sepsis, 1.12% (95% CI: 0.08–3.02%). Significant heterogeneity was observed across studies, with meta-regression revealing that geographical location, publication date, and patient age were significant moderators influencing certain complication rates. This meta-analysis demonstrates that, while systemic and regional complication rates following glioma resection are relatively low, they remain clinically significant. In particular, venous thromboembolism and deep vein thrombosis are notably prevalent. Moreover, significant heterogeneity—shaped by geography, publication date, and patient age—underscores the need for tailored perioperative strategies and further research.


  • Open Access

    Pharmacotherapy for Alcohol Use Disorder: Enhancing Health and Treatment Outcomes

    by Katarzyna Moczyróg, Aleksandra Sierpińska, Agata Jaksz, Maria Jasiewicz, Patrycja Karnas-Bogacka, Marta Malicka, Aleksandra Kozioł, Piotr Mól

    Introduction and Objective: Alcohol Use Disorder (AUD) combines alcohol abuse and dependence into a single condition characterized by an inability to control alcohol consumption despite its negative consequences. Treatment for AUD includes both pharmacological and behavioral therapies aimed at achieving complete abstinence. This paper reviews pharmacological treatment options and their clinical effectiveness. Given the increasing prevalence of AUD globally, including in Poland, understanding the availability, efficacy, and cost of these treatments is essential to improve patient outcomes. Review methods: This review analyzes current literature on pharmacological treatments for AUD, including medications approved by FDA and EMA. Sources include peer-reviewed articles and clinical trials. Results: Naltrexone and nalmefene have been shown to be effective in reducing alcohol consumption and cravings, while acamprosate and topiramate are particularly effective in relapse prevention and maintaining abstinence. Gabapentin is effective in treating alcohol withdrawal symptoms, while baclofen, mifepristone, and N-acetylcysteine show promising results but require further research. Ondansetron has been documented as effective in treating young patients with early-onset AUD, and varenicline effectively reduces alcohol cravings in individuals with nicotine dependence. The disulfiram implant is ineffective in treating alcohol dependence and maintaining abstinence, with its action primarily based on the fear of a disulfiram reaction. Conclusions: Pharmacological treatments for AUD, combined with behavioral therapy, help reduce alcohol consumption or maintain abstinence. Individualized therapy selection is crucial, taking into account the patient's health status and the presence of other conditions. Further research is required to optimize treatment, both in terms of pharmacological mechanisms and better tailoring the therapy to the specific needs of individual patients.

  • Open Access

    The importance of stem cells in the treatment of type 1 diabetes, type 2 diabetes and diabetes complications

    by Monika Kamińska, Maria Jasiewicz, Magdalena Miernik-Skrzypczak, Aleksandra Spyra, Marta Malicka, Natalia Dąbrowska, Aleksandra Kozioł, Katarzyna Moczyróg

    Introduction and Purpose. Diabetes, characterized by hyperglycemia due to impaired insulin production or action, leads to significant complications like diabetic retinopathy (DR) and diabetic foot syndrome (DFS). Current treatments manage symptoms but do not fully address disease progression. Stem cells, with their regenerative potential and immunomodulatory properties, represent a promising avenue for treating diabetes and its complications. This study explores the use of stem cell therapy in managing type 1 and type 2 diabetes, DR, and DFS. Material and Method. The study reviewed existing literature on the application of stem cells in diabetes treatment. More than 30 articles addressing these issues were analyzed. They were found using the PubMed search engine, and the time frame of these publications covered the last 20 years. Results. Stem cells demonstrated significant potential in diabetes management. For type 1 diabetes, MSCs reduced inflammation, preserved pancreatic islet function, and decreased insulin requirements without major adverse effects. Pluripotent stem cells showed promise in islet transplantation, achieving stable glycemic control in clinical trials. In type 2 diabetes, stem cell therapy improved insulin sensitivity and reduced insulin dependency, with evidence of β-cell regeneration. Complications like diabetic foot ulcers and retinopathy also responded positively to stem cell treatments. MSCs improved wound healing by enhancing tissue regeneration and reducing inflammation, while retinal therapies showed promise in slowing disease progression and repairing damaged vasculature. Conclusions. Stem cell therapies offer a promising approach for diabetes and its complications, particularly for regenerative applications in DR and DFS. While initial results are encouraging, further large-scale studies are needed to optimize protocols, assess long-term safety, and establish standardized clinical applications.


  • Open Access

    Vitamin D Supplementation in Selected Autoimmune Diseases

    by Monika Kamińska, Aleksandra Kozioł, Magdalena Agata Miernik-Skrzypczak, Natalia Dąbrowska, Adrian Uchto, Patrycja Karnas-Bogacka, Marta Katarzyna Malicka, Maria Jasiewicz, Katarzyna Moczyróg

    Introduction and Objective. In recent years, awareness of the problem of vitamin D deficiency in the human body has been steadily increasing. There is a growing emphasis on investigating the effects of vitamin D supplementation both in the prevention of autoimmune diseases and in the course of existing diseases. The aim of this study is to highlight and discuss the role of vitamin D supplementation in selected autoimmune diseases.Review methods. The publication is a narrative review. The PubMed electronic database was used to review the literature. To ensure the highest substantive value, the focus was mainly on studies from the last 8 years, with only 6 studies published before 2016, concerning autoimmune diseases.Results. There are still lots of unknowns when it comes to physiology and the role that vitamin D plays in our body and deepening the knowledge of its functions would definitely help prevent many diseases concerning various systems such as musculoskeletal, immune and nervous systems. Wide range of studies have already proven that appropriate supplementation of vitamin D prevents complications and exacerbations of disorders like rheumatoid arthritis, Hashimoto’s thyroiditis, ulcerative colitis, type 1 diabetes and multiple sclerosis. Unfortunately there is no unambiguous evidence of noticeable improvement in the patients suffering from psoriasis after taking vitamin D. There is a huge need for developing guidelines which would establish specific supplementation protocols considering various factors since it is inexplicably difficult to obtain an optimal level of vitamin D in our body.Summary. The increasing prevalence of autoimmune diseases in the population, their coexistence with vitamin D deficiency, and the scientifically proven impact of this vitamin on the body imply the need for an in-depth analysis of the relationship between its supplementation and the prevention and modification of the course of autoimmune diseases.